AstraZeneca HQ scheme hit by further delays

By Hamish Champ2018-08-23T12:57:00

Pharma giant switches from Skanska to Mace as completion is put back to 2020

Further delays to the construction of pharmaceutical giant AstraZeneca’s new headquarters in Cambridge could push the building’s final price tag to more than £500m.

And following a review of the project, Skanska has been replaced by Mace as construction manager for the scientific fit-out and commissioning phase of the project.

Already registered? Login here

To continue enjoying Building.co.uk, sign up for free guest access

Existing subscriber? LOGIN

Stay at the forefront of thought leadership with news and analysis from award-winning journalists. Enjoy company features, CEO interviews, architectural reviews, technical project know-how and the latest innovations.

Limited access to building.co.uk
Breaking industry news as it happens
Breaking, daily and weekly e-newsletters

Get your free guest access SIGN UP TODAY

Subscribe now for unlimited access

Subscribe to Building today and you will benefit from:

Unlimited access to all stories including expert analysis and comment from industry leaders
Our league tables, cost models and economics data
Our online archive of over 10,000 articles
Building magazine digital editions
Building magazine print editions
Printed/digital supplements

Subscribe now for unlimited access.

View our subscription options and join our community